CCL18 and interstitial lung disease: A combination of MMP-7, pulmonary and activation-regulated chemokine (PARC), and surfactant-protein D (SP-D) increased the predictive value of clinical features, positive rheumatoid factor, and anti-cyclic citrullinated peptide antibodies for RA-ILD (38).